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OBJECTIVE AND PERSPECTIVE: To determine
the economic impact of Bipolar Disorder (BD) from
an employer perspective. METHODS: Medical,
pharmacy, workers’ compensation (WC), short- and
long-term disability (STD, LTD), and sick leave (SL)
costs were examined in a database consisting of
2001–2002 claims, payroll, and demographic data
from more than six large US based employers.
Regression modeling was used to measure the cost
differences between employees with BD and
employees without BD while controlling for age,
tenure, gender, salary, region, and other factors.
RESULTS: Data were available for 761 employees
with BD and a control group of 229,145 employees
without BD. The BD group had higher costs with a
217% difference ($6836) summed across all meas-
ures (P £ 0.05). The individual differences in medi-
cal and pharmacy costs were $3860 and $1866,
respectively. Work absence costs had differences of
$80 (SL), $254 (WC), $668 (STD), and $108
(LTD). CONCLUSIONS: The impact of BD can be
costly, not only in terms of healthcare costs, but also
in its impact on lost productivity due to absentee-
ism. Employer-based interventions focusing on
managing BD should be evaluated and implemented
to manage potential short- and long-term economic
impact.
